EUDA Market Analysis

Overview

Fundamentals

P/E ratioForward 11.30
EPS (TTM)$-1.480.0% YoY
Profit margin-40.7%REAL ESTATE
Market cap$56.2MMicro cap

Valuation

Forward P/E
11.30
PEG ratio
P/B
P/S (TTM)
8.24
EV/EBITDA
-25.90

Profitability & growth

ROE (TTM)
0.0%
Operating margin
-34.8%
Revenue growth YoY
78.9%
Dividend yield
Beta
0.56
Last earnings
Oct 1, 2025 · Estimate $0.00 · Reported $-0.03
Analyst estimate. Actual results often differ.

Ratios are point-in-time. Historical metrics — no guarantees about what comes next.

News & Sentiment

Page 1 of 3 · 50 total

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

About EUDA Health Holdings Limited

EUDA Health Holdings Limited is a biopharmaceutical innovator dedicated to the discovery, development, and commercialization of transformative therapies for rare diseases and unmet medical needs. The company utilizes cutting-edge technologies and maintains a strong clinical pipeline, emphasizing supportive care and immune modulation. With a deep commitment to research and development, EUDA is strategically positioned to drive healthcare advancements, improve patient outcomes, and broaden access to vital medical treatments.

Classification

Exchange
NASDAQ
Country
USA
Currency
USD

Company profile

HQ
60 KAKI BUKIT PLACE, SINGAPORE, SINGAPORE
Fiscal year end
December
Latest quarter
Sep 30, 2025
Market cap$56.2M
Shares outstanding$3.0M
52W high$86.00
52W low$5.26

We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer